Having dedicated protocol templates for non-interventional studies (RWE studies) and clinical trials is a must rather than a ‘nice to have’ for several reasons:
- Different Objectives and Designs: Clinical trials and non-interventional studies have distinct objectives and designs. Clinical trials are designed to test the efficacy and safety of a new treatment under controlled conditions. In contrast, non-interventional RWE studies observe and analyse the outcomes of treatments in real-world settings without the researcher influencing or altering standard care practices.
- Regulatory Compliance: Clinical trials are subject to stringent regulatory requirements, including those set by the FDA, EMA, and other health authorities. These regulations ensure patient safety and data integrity and require specific protocol elements, such as detailed inclusion and exclusion criteria, randomization procedures, and stringent data collection methods. RWE studies, while also regulated, have different compliance requirements.
- Data Collection and Analysis: Clinical trials often involve rigorous data collection and analysis methods, including controlled environments, placebo controls, and double-blinding. RWE studies, on the other hand, typically rely on data from healthcare databases, patient registries, or routine clinical practice. Dedicated templates ensure that the protocols for each study type include appropriate guidelines for data collection, handling, and analysis.
- Risk Management: Different study types have different risk profiles. Clinical trials often involve unapproved treatments, requiring detailed risk management plans. RWE studies might involve fewer direct risks to participants but require careful consideration of data privacy and ethical concerns in observational settings. Separate templates can ensure that risk management is appropriately addressed in each type of study.
- Stakeholder Expectations: Clinical trials are often viewed as the gold standard for evidence generation, whereas RWE studies provide complementary insights into how treatments work in everyday clinical practice. Having distinct templates helps in clearly communicating the purpose, scope, and limitations of each study type to stakeholders.
- Efficiency and Clarity: Dedicated templates streamline the protocol development process for each study type. They ensure that researchers consider all relevant aspects and adhere to best practices specific to the study design. This clarity and efficiency can expedite the study approval process, reduce administrative burdens, and enhance the quality of the research.
In summary, having separate protocol templates for non-interventional studies and clinical trials is essential for aligning with specific study objectives, meeting regulatory requirements, ensuring appropriate data collection and analysis methods, managing risks effectively, meeting stakeholder expectations, and enhancing overall research efficiency and clarity.
Share this story...
Lithuania – Leaping into Digital Health Future with RWE and RWD Innovations
RWE 201 - Lithuania – Leaping into Digital Health Future with RWE and RWD Innovations EU Partnership Agreement: https://ec.europa.eu/commission/presscorner/detail/en/ip_22_2547Lithuania is actively implementing Real-World Evidence (RWE) and Real-World Data (RWD) [...]
RWE Guest Post – Does Real-World Evidence Play a Role in G-BA’s Benefit Assessments in Germany?
RWE 201 - RWE Guest Post - Does real-world evidence play a role in G-BA's benefit assessments in Germany? Guest: Anja PownellGerman Market Access – Simplified: https://germanmarketaccesssimplified.com/IntroductionThe German [...]
RWE Guest Post – Germany – From Concept to Evaluation: The Journey of RWE requests by the G-BA
RWE 201 - RWE Guest Post – Germany - From Concept to Evaluation: The Journey of RWE requests by the G-BA Guest: Anja PownellGerman Market Access – Simplified: [...]
Spain – Championing the Ethical and Responsible Use of Real World Data
RWE 201 - Spain – Championing the Ethical and Responsible Use of Real World Data Farmindustria Code of Conduct: https://codigoprotecciondatos.farmaindustria.org/sites/medicamentosinnovadores/docs/PRODF484450.pdfIn 2022, the Spanish Data Protection Agency (AEPD) gave its [...]
EU – RWD/RWE is Embedded into the New EU Medicines Regulations
RWE 201 - EU – RWD/RWE is Embedded into the New EU Medicines Regulations Coming Soon…New EU Medicines Regulations: https://health.ec.europa.eu/medicinal-products/pharmaceutical-strategy-europe/reform-eu-pharmaceutical-legislation_enIn 2023, the European Commission undertook an ambitious overhaul of [...]
EU – EU’s Action Plan for Real-World Data (RWD) & RWE
RWE 201 - EU – EU's Action Plan for Real-World Data (RWD) & RWE The European Union has embarked on an ambitious journey to weave Real World Evidence (RWE) [...]







